C4 Therapeutics Inc (CCCC)

$3.94 +0.08 (2.07%)
Market Cap 272.47M
Revenue (ttm) 20.76M
Net Income (ttm) -132.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -638.20%
Debt to Equity Ratio 0.00
Volume 2,679,400
Avg Vol 1,708,254
Day's Range N/A - N/A
Shares Out 70.59M
Stochastic %K 64%
Beta 2.96
Analysts Strong Sell
Price Target $15.44

Latest News on CCCC

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 5 weeks ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 2 months ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2024, 4:01 PM EDT - 2 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 3 months ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 3 months ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 4 months ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 4 months ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 4 months ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 5 months ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 6 months ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 6 months ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 6 months ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 7 months ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 9 months ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 10 months ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 10 months ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 11 months ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 11 months ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 11 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 1 year ago

C4 Therapeutics Announces Chief Financial Officer Succession

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 8, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 15, 2023, 1:58 AM EDT - 1 year ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jul 5, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Jun 20, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 4, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 23, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

Feb 8, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 30, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 3, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

Sep 29, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

Sep 26, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 4, 2022, 8:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.

Aug 2, 2022, 8:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

May 16, 2022, 8:00 AM EDT - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 5, 2022, 8:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 4, 2022, 8:50 AM EDT - 2 years ago

C4 Therapeutics: Poor Data Destroyed Preclinical Promise